Lakewood-Amedex Biotherapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 0.2 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 473.94K
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Details
| Name | Lakewood-Amedex Biotherapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 5 |
| Founded | 2006 |
| Ceo | Kelvin Cooper |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US51255A2015 |
| Cusip | 51255A201 |
| Cik | 2079272 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Kelvin Cooper Ph.D. | Chief Executive Officer, SVice President of Research and Development and Director |
| Peter F. Ceccacci | Chief Financial Officer and Vice President of Administration |
| Dr. Thomas Balzer M.D., Ph.D. | Chief Medical Officer and SVice President of Clinical Development |
| Tara Endress | Project Manager and Accounting Manager |
| Daniel Kontoh-Boateng | Investor Relations |
Contact
| Address | 8031 Cooper Creek Blvd., Suite 103, University Park, Florida 34201, United States |
| Phone | 941 225 2515 |
| Website | https://lakewoodamedex.com |